Biolinerx
NASDAQ: BLRXModi'In · Israel corporation
Bioline Rx develops therapies for patients with cancer and rare diseases, leveraging a team with expertise spanning drug development from chemistry through clinical trials to commercialization.
Founders & leadership
BJ
Barbara Jean BormannNamed on SEC filing
MZ
Mali ZeeviNamed on SEC filing
RH
Raphael HofsteinNamed on SEC filing
AM
Avraham MolchoNamed on SEC filing
PA
Philip A. SerlinNamed on SEC filing
AS
Aharon SchwartzNamed on SEC filing
NB
Nurit BenjaminiNamed on SEC filing
AV
Abi Vainstein-HarasNamed on SEC filing
MJ
Michael J. AnghelNamed on SEC filing
SP
Sandra PanemNamed on SEC filing
ES
Ella SoraniNamed on SEC filing
RD
Rami DarNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$17.1M disclosed across 3 rounds · 2020–2026
▶$3.8MraisedSep 2026 · 1 investors · BiotechnologyRule 506(b)
▶$3.8MraisedSep 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Philip A. SerlinExecutive Officer
- Mali ZeeviExecutive Officer
- Ella SoraniExecutive Officer
- Aharon SchwartzDirector
- Rami DarDirector
- BJ BormannDirector
- Raphael HofsteinDirector
- Avraham MolchoDirector
- Sandra PanemDirector
- Shaoyu YanDirector
- Gal CohenDirector
- Offering amount
- $3.8M
- Amount sold
- $3.8M
- Sales commissions
- $262.5K
- Placement agents
- Chardan Capital Markets LLC
- First sale
- Aug 2026
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$9MraisedJun 2020 · 6 investors · PharmaceuticalsRule 506(b)
▶$9MraisedJun 2020 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Barbara Jean BormannDirector
- Mali ZeeviExecutive Officer
- Raphael HofsteinDirector
- Avraham MolchoDirector
- Philip A. SerlinExecutive Officer
- Aharon SchwartzDirector
- Nurit BenjaminiDirector
- Abi Vainstein-HarasExecutive Officer
- Michael J. AnghelDirector
- Sandra PanemDirector
- Ella SoraniExecutive Officer
- Offering amount
- $9M
- Amount sold
- $9M
- Sales commissions
- $630K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- May 2020
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$4.4MraisedJun 2020 · 5 investors · PharmaceuticalsRule 506(b)
▶$4.4MraisedJun 2020 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Abi Vainstein-HarasExecutive Officer
- Avraham MolchoDirector
- Philip A. SerlinExecutive Officer
- Nurit BenjaminiDirector
- Michael J. AnghelDirector
- Mali ZeeviExecutive Officer
- Ella SoraniExecutive Officer
- Sandra PanemDirector
- Raphael HofsteinDirector
- Barbara Jean BormannDirector
- Aharon SchwartzDirector
- Offering amount
- $4.4M
- Amount sold
- $4.4M
- Sales commissions
- $307.5K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- May 2020
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Biolinerx do?
- Bioline Rx develops therapies for patients with cancer and rare diseases, leveraging a team with expertise spanning drug development from chemistry through clinical trials to commercialization.
- How much funding has Biolinerx raised?
- Biolinerx has disclosed $17.1M raised across 3 rounds.
- Where is Biolinerx headquartered?
- Biolinerx is headquartered in Modi'In.